ImmuPharma PLC

Analyst sees 'clear rationale' for ImmuPharma to move forward with Lupuzor

The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on ImmuPharma PLC (LON:IMM) and its flagship drug Lupuzor - a treatment for the autoimmune disease Lupus.

Dr Malik says despite not meeting its primary end point in a recent phase III trial, the response rate overall compares well to a number of other pivotal studies and has an excellent safety profile.

Worldwide, there are 5mln people with Lupus, 1.5mln of them in the US, Europe and Japan.

Quick facts: ImmuPharma PLC

Price: £0.10

Market: AIM
Market Cap: £16.26 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...



Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

Dr Navid Malik, Head of Life Sciences Research, tells Proactive London's Andrew Scott the recent positive update for AstraZeneca's lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly...

1 week, 2 days ago

2 min read